Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination
- 22 November 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (26), 6692-6699
- https://doi.org/10.1021/jm070897b
Abstract
Octahedrally configured diaminedichloro- and diamineoxalatoplatinum(IV) complexes with axial hydroxo ligands were carboxylated with succinic or glutaric anhydride. The free, uncoordinated carboxylic acid groups were further derivatized with amines and alcohols to the respective amides and esters and characterized in detail by elemental analysis, mass spectrometry, and multinuclear (1H, 13C, 15N, and 195Pt) NMR spectroscopy. Cytotoxicity of the complexes was studied in four human cancer cell lines derived from ovarian carcinoma (CH1, SK-OV-3), cervical carcinoma (HeLa), and colon carcinoma (SW480) by means of the MTT assay. Structure–activity relationships revealed a low activity for platinum complexes with underivatized carboxylic acid moieties and amide derivatives displaying the hydroxyethylamino residue. Within the series of amides, cyclopentylamino analogues were equipped with the highest cytotoxic potential. However, ester derivatives yielded IC50 values mostly in the low micromolar range and comparable to those of cisplatin. DNA platination studies of selected complexes revealed a high DNA platination capacity in parallel to a high cytotoxic potential and vice versa.Keywords
This publication has 22 references indexed in Scilit:
- Basis for Design and Development of Platinum(IV) Anticancer ComplexesJournal of Medicinal Chemistry, 2007
- Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor TissueAnti-Cancer Agents in Medicinal Chemistry, 2007
- The Role of Sulfur in Platinum Anticancer ChemotherapyAnti-Cancer Agents in Medicinal Chemistry, 2007
- Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical ApproachesCurrent Medicinal Chemistry, 2005
- Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate CancerOncology, 2005
- High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitroBiochemical Pharmacology, 2005
- Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)Investigational New Drugs, 2005
- Recent Developments in the Field of Tumor-Inhibiting Metal ComplexesCurrent Pharmaceutical Design, 2003
- Tumour-inhibiting platinum complexes—state of the art and future perspectivesReviews of physiology, biochemistry and pharmacology, 2003
- Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?Chemical Reviews, 1999